Crossmark

Response to: Letter to the Editor Regarding ‘Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study’

Crossref DOI link: https://doi.org/10.1007/s12325-026-03493-8

Published Online: 2026-01-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alcázar-Navarrete, Bernardino

Figueira-Gonçalves, Juan Marco

Corregidor-García, Carmen

Fitas, Eunice

Sánchez-Covisa, Joaquín
License Information

Text and Data Mining valid from 2026-01-27

Version of Record valid from 2026-01-27
More Information

Article History

Received: 8 December 2025

Accepted: 2 January 2026

First Online: 27 January 2026

Declarations

:

: Bernardino Alcázar-Navarrete declares conflicts of interest for having received consulting fees, research grants, or lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, GSK, Laboratorios Bial, Laboratorios Menarini, and Sanofi. Juan Marco Figueira-Gonçalves has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, Laboratories Esteve, MundiPharma, Boehringer Ingelheim, Ferrer, Menarini, Rovi, GSK, Chiesi, Novartis, and Gebro Pharma. Carmen Corregidor-García, Eunice Fitas, and Joaquín Sánchez-Covisa are employees of AstraZeneca.

: This letter does not report new studies with human participants or animals. The ORESTES study was conducted with appropriate approval from an Ethics Committee as detailed in the original publication.

Document is current

Any future updates will be listed below